

COLLECTION DATE (REQUIRED)

If date of collection is not provided, three calendar days before specimen receipt will be used (for specimens stored longer than 30 days, the day of archive retrieval will be used as the date of service)

PATIENT INFORMATION

Legal Name (Last, First, MI)		Date of Birth (Month/DD/YYYY)	Sex Assigned at Birth ☐ F ☐ M	Gender (optional) ☐ Man ☐ Woman ☐ Nonbinary ☐ Self-described
Genetic Ancestry: ☐ Ashkenazi Jewish ☐ Asian ☐ Black/African American ☐ French Canadian/Cajun ☐ Hispanic/Latino ☐ Mediterranean ☐ Middle Eastern ☐ Native American ☐ Pacific Islander ☐ Portuguese ☐ White ☐ Unknown ☐ Other:				MRN/National ID
Address			State/Province	Country
Mobile #		Email		

SPECIMEN INFORMATION* (Please see ambrygen.com/specimen-requirements for details)

☐ Personal history of allogenic bone marrow or peripheral stem cell transplant	
Specimen ID	Specimen Type

* Fetal specimens, cord blood, buccal samples, and POC samples are not accepted from International clients.

INDICATION(S) FOR TESTING

ICD-10 code(s):

ORDERING LICENSED PROVIDER/SENDING FACILITY (Each listed person will receive a copy of the report)

Facility Name (Facility Code)		Address	
State /Province		Country	Phone
Ordering Licensed Provider Name (Last, First)(Code)	NPI# (US only)	Phone	Fax/Email

ADDITIONAL RESULTS RECIPIENTS

Genetic Counselor or Other Medical Provider Name (Last, First) (Code)	Phone/Fax/Email
Genetic Counselor or Other Medical Provider Name (Last, First) (Code)	Phone/Fax/Email

CONFIRMATION OF INFORMED CONSENT AND MEDICAL NECESSITY FOR GENETIC TESTING

I confirm that the genetic test ordered is medically appropriate. All information on this TRF is true to the best of my knowledge. I also confirm that the patient has consented to proceed with genetic testing, including the transfer and processing of their sample and personal/sensitive information in the United States. I agree to allow Ambry Genetics to facilitate the provision of pre-test genetic counseling services by a third-party service, as required by the patient's insurance provider.

Signature Required for Processing Medical Professional Signature:	Date:
--	-------

BILLING

☐ INSURANCE BILLING (Include copy of both sides of insurance card)	
☐ INSTITUTIONAL BILLING	
Facility Name	☐ Send invoice to facility address above
Address	
Contact Name	
Phone Number	Email/Fax

☐ PATIENT PAYMENT	☐ Check (Payable to Ambry Genetics)	☐ Credit Card (Call 949-900-5795)
---	--	--

Patient Acknowledgement: I acknowledge that the information provided by me is true and correct. For direct insurance billing: I authorize my insurance benefits to be paid directly to Ambry Genetics Corporation (Ambry), authorize Ambry to release medical information concerning my testing to my insurer, to be my designated representative for purposes of appealing any denial of benefits as needed and to request additional medical records for this purpose. I understand that I am financially responsible for any amounts not covered by my insurer and responsible for sending Ambry money received from my health insurance company.

☐ I agree to be contacted regarding future research studies for which I may be a candidate. Any future research projects will be subject to a separate informed consent process and participation is voluntary. Learn more about Ambry's privacy practices at <https://www.ambrygen.com/legal/notice-of-privacy-practices>.

For patient payment by credit card: I hereby authorize Ambry Genetics Corporation to bill my credit card as indicated above.

Patient Signature (I agree to terms above):	Date:
--	--------------

Patient Consent To Testing

I acknowledge and agree that my health care provider has ordered genetic testing for processing at Ambry Genetics, a laboratory based in the United States and subject to U.S. based privacy laws, including the Health Insurance Portability and Accountability Act (HIPAA). I have provided my health care provider with the appropriate consent acknowledgment and documentation as required under the applicable laws in my country of residence for my genetic information to be sent to and processed in the United States. I have reviewed Ambry's Notice of Privacy Practices and understand and agree to the use of my health information in accordance with such privacy practices. I understand that I can exercise my rights to privacy consistent with HIPAA and Ambry's privacy notices.

Patient Signature (I agree to terms above):	Date:
--	--------------

PLEASE SUBMIT THE FOLLOWING WITH THE TRF:

1. Clinic Notes 2. Pedigree 3. Insurance Card and Authorization Documents

CLINICAL HISTORY
PLEASE ATTACH PEDIGREE /CLINICAL CONSULTATION NOTES, IF AVAILABLE

Birth and Neonatal History ☐ Not Applicable Gestational age at birth: _____ Birth weight: _____ Head circumference at birth (if available): _____ ☐ Congenital anomalies, explain: _____ ☐ Positive newborn screen, explain: _____ Seizure History ☐ Not Applicable Age at first unprovoked seizure (first seizure without fever or other acute metabolic or structural cause): _____ Seizure types (choose all that apply): ☐ Infantile/epileptic spasms ☐ Myoclonic ☐ Generalized tonic clonic ☐ Tonic ☐ Typical absence ☐ Focal seizures ☐ Atonic ☐ Atypical absence Are seizures: ☐ refractory ☐ well-controlled Has this patient been diagnosed with an epilepsy syndrome? ☐ yes ☐ no ☐ unknown If yes, please specify: _____ Pulmonology History ☐ Not Applicable ☐ Positive newborn screen ☐ CBAVD ☐ Meconium ileus ☐ Infections: _____ ☐ Sweat chloride: _____mmol/L ☐ Sweat chloride: ☐ <40 ☐ 40-60 ☐ >60 ☐ Pancreatic insufficiency IRT level: _____ ☐ Respiratory distress, explain: _____ ☐ Respiratory assistance devices: _____ ☐ Ultrasound findings: _____	Developmental History ☐ Not Applicable Developmental delay: ☐ yes ☐ no ☐ unknown Delay prior to seizure onset: ☐ yes ☐ no ☐ unknown ☐ N/A Type of delay (choose all that apply): ☐ motor ☐ language ☐ global Intellectual disability: ☐ yes ☐ no ☐ unknown Regression or plateau: ☐ yes ☐ no ☐ unknown Does patient meet DSM-V diagnostic criteria for an autism spectrum disorder?: ☐ yes ☐ no ☐ unknown Cardiac History ☐ Not Applicable Sudden cardiac arrest ☐ Y ☐ N (if yes): # Episodes: _____ Age first incident: _____ Syncope ☐ Y ☐ N If yes, # Episodes: _____ Age first incident: _____ History of cardiomyopathy ☐ Y ☐ N Age at dx: _____ Cardiomyopathy type: _____ History of Arrhythmia ☐ Y ☐ N Age at dx: _____ Arrhythmia type: _____ ☐ Congenital heart defect _____ Other History ☐ Not Applicable ☐ Hearing problems: _____ ☐ Vision problems: _____ ☐ Migraine: _____ ☐ Psychiatric: _____ ☐ Hematological: _____ ☐ Suspected genetic condition: _____ ☐ Other clinical findings: _____
---	--

Cancer History ☐ Not Applicable Metastatic: ☐ Yes ☐ No Tumor is ☐ MSI-High or ☐ IHC-Abnormal

Cancer/Tumor	Age at Dx	Pathology and Other Info
Brain		
Breast		Type: ER ☐ (+) ☐ (-) ☐ unk PR ☐ (+) ☐ (-) ☐ unk HER2/neu ☐ (+) ☐ (-) ☐ unk
2nd primary breast		Type: ER ☐ (+) ☐ (-) ☐ unk PR ☐ (+) ☐ (-) ☐ unk HER2/neu ☐ (+) ☐ (-) ☐ unk
Colorectal		Location: _____
Ovarian		☐ Fallopian tube ☐ Primary peritoneal
Melanoma/Skin		
Prostate		Gleason Score: _____
Uterine		
Hematologic*		Type: ☐ Allogenic bone marrow or peripheral stem cell transplant*
Other Cancer		Type: _____
GI polyps		☐ Adenomatous Polyp #: ☐ 1 ☐ 2-5 ☐ 6-9 ☐ 10-19 ☐ 20-99 ☐ 100+ ☐ Other type: Polyp #: ☐ 1 ☐ 2-5 ☐ 6-9 ☐ 10-19 ☐ 20-99 ☐ 100+

*Blood or saliva from patients with active/recent hematological disease will undergo additional review and may not be accepted in some cases. For these, cultured fibroblasts or fresh/fresh frozen normal tissue are preferred. See ambrygen.com/specimen-requirements for details.

PREVIOUS TEST HISTORY (Please include copy of test results if performed at another laboratory) ☐ Limited family history

Known Familial Variant: ☐ Family ☐ Self Gene: _____ Variant (c. and/or p.): _____ Testing Lab: _____ Ambry ID: _____
See instructions on the Supplemental Information Page
 Patient previously tested at Ambry? ☐ Yes ☐ No Family previously tested at Ambry? ☐ Yes ☐ No
 Name: _____ DOB: _____ Relation: _____

FAMILY MEMBER INFORMATION (Completion of this section is required for orders including parental samples)

Mother - Name: _____ DOB: _____ ☐ unaffected ☐ affected, list symptoms/dx: _____ Dx age: _____
 Father - Name: _____ DOB: _____ ☐ unaffected ☐ affected, list symptoms/dx: _____ Dx age: _____

Relationship to Patient	Mat	Pat	Age at Dx	Family Testing and Cancer Type Details	Reason relative has not been tested
	☐	☐			☐ Deceased ☐ Declines ☐ No Contact
	☐	☐			☐ Deceased ☐ Declines ☐ No Contact
	☐	☐			☐ Deceased ☐ Declines ☐ No Contact

International Test Requisition Form - Page 3 of 6

If this TRF is sent to Ambry without or ahead of the sample, it will be treated as a preverification. If test ordered is different than the test preverified, we will honor what is on the TRF order form with the sample. Preverification will only be performed for ExomeNext® and GenomeNext™ testing.

CANCER TEST ORDERS							
Primary Test Order							
REQUIRED: Select a Primary Test Order							
For Patients Meeting <i>BRCA1</i> /2 Testing Criteria				For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (polyposis)			
☐ <i>BRCA1</i> /2 test				Polyposis test: ☐ <i>APC</i> / <i>MUTYH</i>			
For Patients Meeting Colorectal Cancer Syndrome Testing Criteria (Lynch)				☐ Other: _____			
Lynch Syndrome test: ☐ <i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i> , <i>EPCAM</i>				☐ None of the above (patient does not meet any genetic testing criteria)			
Select an Optional Supplemental Test (Per payer policy, all tests in this section will be processed and billed separately.)							
Order	Test Code	Test Name	Description	Order	Test Code	Test Name	Description
☐	8857	BRCANext®	Breast & gynecologic cancer test	☐	8821	ColoNext®	Colorectal cancer & polyposis test
Add on: ☐ Limited Evidence				Add on: ☐ Limited Evidence			
☐	8836	BRCAPlus®	STAT breast management test	☐	9511	CustomNext-Cancer® Notes: _____ _____ _____	Custom test Gene content is required. Use CustomNext-Cancer supplemental form for guidance.
☐	8824	CancerNext®	Pan-cancer test				
☐	8875	CancerNext-Expanded®	Pan-cancer test				
Add on: ☐ Limited Evidence							
Add on: ☐ Pancreatitis							
Other Supplemental Test Options (Select if applicable)							
☐ +RNAinsight® (Not available with BRCAPlus, or STAT orders; PAXgene® tube required for RNA)							
Order	Test Name	Test Code	Description	Order	Test Name	Test Code	Description
Breast and/or Ovarian Cancer				Gastrointestinal Cancer (Cont.)			
☐	<i>ATM</i>	9014	Ataxia-telangiectasia	☐	<i>MLH1</i>	8508	Lynch syndrome
☐	<i>BRCA1</i> /2	8838	Hereditary breast and ovarian cancer	☐	<i>MSH2</i> + <i>EPCAM</i> del/dup	8510	Includes <i>MSH2</i> inversion
☐	<i>CHEK2</i>	9016		☐	<i>MSH2</i> inversion	2226	Lynch syndrome
☐	<i>DICER1</i>	5260		☐	<i>MSH6</i>	8512	Lynch syndrome
☐	<i>PALB2</i>	2366		☐	<i>MUTYH</i>	4661	<i>MUTYH</i> -associated polyposis
☐	<i>PTEN</i>	2106	<i>PTEN</i> -related disorders (including Cowden syndrome)	☐	<i>PMS2</i>	4646	Lynch syndrome
☐	<i>TP53</i>	2866	Li-Fraumeni syndrome	☐	<i>STK11</i>	2766	Peutz-Jeghers syndrome
Endocrine Tumors				Genitourinary Cancer			
☐	<i>MEN1</i>	2646	Multiple endocrine neoplasia type 1	☐	<i>BAP1</i>	9044	
☐	<i>RET</i> gene sequence	2680	Multiple endocrine neoplasia type 2	☐	<i>FH</i>	6301	Hereditary leiomyomatosis and renal cell cancer
Gastrointestinal Cancer				☐	<i>FLCN</i>	5921	Birt-Hogg-Dubé syndrome
☐	<i>APC</i>	3040	Familial adenomatous polyposis	☐	<i>VHL</i>	2606	Von-Hippel Lindau disease
☐	<i>APC</i> and <i>MUTYH</i> concurrent	8726	Adenomatous polyposis	☐	<i>TSC1</i> and <i>TSC2</i>	5904	Tuberous sclerosis complex
☐	<i>BMPRI1A</i> and <i>SMAD4</i> concurrent	8604	Juvenile polyposis syndrome	Skin Cancer/Melanoma			
☐	<i>CDH1</i>	4726	Hereditary diffuse gastric cancer	☐	<i>CDKN2A</i> and <i>CDK4</i> concurrent	4708	Familial atypical multiple mole melanoma (FAMMM)
☐	<i>EPCAM</i> del/dup	8519	Lynch syndrome	☐	<i>PTCH1</i>	5684	Gorlin syndrome
☐	Lynch syndrome (concurrent)	8517	<i>MLH1</i> , <i>MSH2</i> , <i>MSH6</i> , <i>PMS2</i> + <i>EPCAM</i> del/dup	Other Hereditary Cancer Testing			
				☐	<i>NF1</i>	5704	Neurofibromatosis type 1
				☐	<i>NF2</i>	9024	Neurofibromatosis type 2
				☐	<i>RB1</i>	5426	Hereditary retinoblastoma
				☐	<i>SMARCB1</i>	7180	Schwannomatosis
Other Single Syndrome Orders							
☐ Please visit ambrygen.com/hereditary-cancer-single-gene-tests for details.							
Test Code(s): _____ Gene/Test Name(s): _____							

International Test Requisition Form - Page 4 of 6

Order	Test Name	Test Code	Description	Order	Test Name	Test Code	Description						
CARDIOLOGY													
Comprehensive Cardiovascular Panels				Familial Hypercholesterolemia									
☐	CardioNext®	8911	92 genes for hereditary cardiomyopathies and arrhythmias	☐	FHNNext®	8680	4 genes (APOB, LDLR, LDLRAP1, PCSK9)						
☐	CustomNext-Cardio®	9520	Up to 167 genes related to hereditary cardiomyopathies, arrhythmias, TAAD, HHT, Noonan, and lipidemias. Required: completed CustomNext-Cardio supplemental form. ambrygen.com/forms	☐ Check this box if you would like to have the <i>SLC01B1</i> c.521T>C polymorphism reported with FHNNext, which has been associated in medical literature with statin-induced myopathies									
Arrhythmia Panels				☐	FCSNext (Familial Chylomicronemia Syndrome)	8920	APOA5, APOC2, GPIHBP1, LMF1, LPL						
☐	LongQTNext™	8890	17 genes for long QT, Brugada and short QT syndromes	☐	Sitosterolemia	8930	ABCG5, ABCG8						
☐	RhythmNext®	8900	42 genes for long QT syndrome, Brugada and short QT syndromes, CPVT and ARVC	Aneurysms and Related Disorders									
☐	CPVTNext®	8902	4 genes for catecholaminergic polymorphic ventricular tachycardia	☐	TAADNext®	8789	35 genes for thoracic aortic aneurysms/dissections, Marfan syndrome, Ehlers-Danlos and related disorders						
Cardiomyopathy Panels				☐	Marfan reflex to TAADNext	8783	FBN1 reflex to TAADNext						
☐	HCMNext®	8936	30 genes for hypertrophic cardiomyopathy	Hereditary Hemorrhagic Telangiectasia (HHT)									
☐	HCMNext Reflex	8883	MYBPC3, MYH7 reflex to HCMNext	☐	HHTNext®	8672	ACVRL1, ENG, EPHB4, GDF2, RASA1, SMAD4						
☐	DCMNext®	8884	37 genes for dilated cardiomyopathy	Noonan Syndrome									
☐	CMNext®	8887	56 genes for hereditary cardiomyopathy	☐	NoonanNext™	8402	18 genes for RASopathies						
☐	ARVCNext™	8904	11 genes for arrhythmogenic right ventricular cardiomyopathy	Other									
				☐	Transthyretin amyloidosis	1560	TTR						
CLINICAL GENOMICS													
For Reflex or Concurrent Testing: See Reflex or Concurrent Testing section of the Supplemental Information page.													
Test 1: _____		☐ Reflex to	Test 2: _____		☐ Reflex to	Test 3: _____							
		☐ Concurrent with			☐ Concurrent with								
Previously Reported Variants: See instructions for reporting of Previously Reported Variants on the Supplemental Information Page													
Gene: _____		Variant (c. and/or p.): _____		Testing Lab: _____		Ambry ID: _____							
Chromosomal Microarray													
☐	SNP Array	5490	Chromosomal microarray (>2.6 million copy number probes and 750,000 SNP probes)										
Exome and Genome													
! REQUIRED: Select a Primary Test Order													
☐	ExomeNext® ☐ Proband only ☐ Duo ☐ Trio	9900	Exome sequencing	☐	ExomeNext-Rapid®	9999-R	Rapid trio exome sequencing including a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)						
ExomeNext Supplemental Test Options (Primary test order required. See descriptions for details.)													
ACMG Secondary Findings* ☐ Decline		9920	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.	☐	ExomeReveal® RNA Analysis	9990	RNA analysis is available with all ExomeNext orders except for ExomeNext-Rapid. EDTA and PAX-gene RNA tubes are required.						
				☐	Mito DNA	9900-M	Analysis of a defined list of established disease-causing variants in the mitochondrial DNA (mtDNA)						
! REQUIRED: Select a Primary Test Order													
☐	GenomeNext™ ☐ Proband only ☐ Duo ☐ Trio	7000	Genome sequencing including sequencing of mitochondrial DNA (mtDNA)										
GenomeNext Supplemental Test Options (Primary test order required.)													
ACMG Secondary Findings* ☐ Decline		7002	Analysis of genes included in the ACMG Recommended List of secondary findings. Secondary findings results are available free of charge for the proband and each family member who is fully sequenced as part of the duo/trio.	☐	GenomeReveal™ RNA Analysis	7004	RNA analysis is available with all GenomeNext orders. EDTA and PAX-gene RNA tubes are required. Genome Reveal will be added automatically if a PAX tube is provided.						
				*Secondary Findings: Check "decline" to opt-out of the ACMG Recommended List of secondary findings. If left unchecked, secondary findings will be reported.									
ENDOCRINOLOGY													
☐	Hereditary leiomyomatosis renal cell carcinoma	6301	FH	☐	Multiple endocrine neoplasia type 2 and familial medullary thyroid cancer (FMTC)	2680	RET gene sequence						
☐	Multiple endocrine neoplasia type I	2646	MEN1	☐	von-Hippel Lindau disease	2606	VHL						
☐	Neurofibromatosis type 1	5704	NF1										

International Test Requisition Form - Page 5 of 6

GASTROENTEROLOGY							
☐	CFTR gene sequence and deletion/duplication analysis	1007	☐ Report poly T/TG status	☐	Juvenile polyposis syndrome	8604	BMPR1A, SMAD4
☐	Hirschsprung disease (RET-related)	2680	RET gene sequence	☐	Pancreatitis	8022	CFTR, CPA1, CTSC, PRSS1, SPINK1
☐				☐	Peutz-Jeghers syndrome	2766	STK11
HEMATOLOGY/ONCOLOGY							
☐	Shwachman-Diamond syndrome	1440	SBDS				
NEUROLOGY							
☐ Opt-in to Reporting of Variants of Unknown Significance (VUS) For patients undergoing an epilepsy or neurodevelopmental disorder panel, checking this box indicates that VUS identified on the test(s) ordered below will be reported for this patient. If you do not check this box, VUS will NOT be reported.							
☐ Parental samples provided for cosegregation Cosegregation testing of family members is available for the following panels: EpilepsyNext, EpilepsyNext-Expanded, AutismNext, NeurodevelopmentNext							
For Reflex or Concurrent Testing: See Reflex or Concurrent Testing section of the Supplemental Information page.							
Test 1: _____		☐ Reflex to		Test 2: _____		☐ Reflex to	
		☐ Concurrent with				☐ Concurrent with	
Order	Test Name	Test Code	Description	Order	Test Name	Test Code	Description
Epilepsy				Neurodevelopmental Disorders			
☐	EpilepsyNext®	6864	Multigene panel test for epilepsy	☐	AutismNext®	6863	Multigene panel test genes for non-syndromic autism spectrum disorders and/or intellectual disability
☐	EpilepsyNext-Expanded™	6865	Multigene panel test for genes associated with seizures, primarily with neonatal to childhood onset	☐	Autism, macrocephaly	2106	PTEN
Hereditary Neuropathy				☐	Fragile X syndrome	4544	FMR1 repeat expansion analysis and methylation studies
☐	Familial transthyretin amyloidosis	1560	TTR	☐	NeurodevelopmentNext™	6861	Multigene panel test for genes known to cause developmental delay, intellectual disability and/or autism spectrum disorders
Neurocutaneous/Neuro-Oncology Disorders							
☐	Ataxia-telangiectasia	9014	ATM	☐	Neurofibromatosis 2	9024	NF2
☐	HHTNext®	8672	ACVRL1, ENG, EPHB4, GDF2, RASA1, SMAD4	☐	Nevoid basal cell carcinoma syndrome/Gorlin syndrome	5684	PTCH1
☐	Legius syndrome	5724	SPRED1	☐	Tuberous sclerosis complex	5904	TSC1, TSC2
☐	Li-Fraumeni syndrome	2866	TP53	☐	von Hippel-Lindau disease	2606	VHL
☐	Neurofibromatosis 1	5704	NF1				
PULMONOLOGY							
Congenital Central Hypoventilation Syndrome				Primary Ciliary Dyskinesia			
☐	Congenital central hypoventilation syndrome	1580	PHOX2B gene sequence	☐	PCDNext®	8122	21 genes for primary ciliary dyskinesia ☐ Report poly T/TG status
Cystic Fibrosis				Pulmonary Fibrosis			
☐	CFTR gene sequence and deletion/duplication analysis	1007	☐ Report poly T/TG status	☐	Telomere-related pulmonary fibrosis	8140	TERT, TERC
				Respiratory Distress Syndrome			
				☐	Surfactant dysfunction (respiratory distress syndrome)	8100	ABCA3, SFTPB, SFTPC gene sequence
VASCULAR							
☐	HHTNext®	8672	ACVRL1, ENG, EPHB4, GDF2, RASA1, SMAD4	☐	TAADNext®	8789	35 genes for thoracic aortic aneurysms
☐	Marfan syndrome reflex to TAADNext	8783	FBN1 reflex to TAADNext				
KNOWN VARIANT ANALYSIS (Please include a copy of relative's report)							
Gene(s): _____ Variant(s) (c. and/or p.): _____ Relative Name: _____							
Relationship to Relative: _____ Accession # (if tested at Ambry): _____							
Positive control sample: ☐ will be provided ☐ already at Ambry ☐ not available							

Supplemental Information - Page 6 of 6

Electronic ordering is also available via AmbryPort®. Please visit <https://portal.ambrygen.com/login> to log in to the online portal.

Hereditary Cancer Multi-Gene Tests

For current hereditary cancer panel gene content, please visit www.ambrygen.com/providers/oncology/test-menu (linked to QR code below).



Scan for current hereditary cancer panel gene content

Neurology Multi-Gene Tests

For current neurology panel gene content, please visit www.ambrygen.com/providers/neurology/test-menu (linked to QR code below)



Scan for current neurology panel gene content

Specimen Requirements

Blood/saliva from patients with a history of allogenic bone marrow or stem cell transplant cannot be used for genetic testing. Blood/saliva from patients with active hematological disease is not recommended. An alternative specimen may be needed. Please see ambrygen.com/specimen-requirements for details.

Known variant analysis should be accompanied by a copy of the original testing report or internal Ambry testing information (internal Ambry ID, Name/DOB). Please review information about positive controls and other specifics at ambrygen.com/knownvariantanalysis.

Please note that Ambry cannot guarantee the viability of your specimen for testing at our laboratory, given the logistics of international specimen transfer. Testing may not be completed on specimens of inadequate quality due to specimen transfer issues not under Ambry's control, including, but not limited to, delays at customs, or other transfer-related delays. Ambry or your health care provider will reach out to you in such a case to rearrange for a specimen collection and transfer for completion of the ordered test.

Reflex or Concurrent Testing

Concurrent testing is when multiple tests are initiated at the same time. When multiple tests are ordered on the same test requisition form, testing will be run concurrently unless otherwise specified.

Reflex testing is when a subsequent test is initiated pending the outcome of the initial test. Reflex testing may result in delayed reporting of results. Reflex testing is no longer available for Oncology orders.

For reflex test orders:

- Any diagnostic finding at any step will result in cancellation of any subsequent reflex tests.
- Non-diagnostic findings (including VUS or Uncertain results) will automatically reflex to the subsequent test.
- Secondary findings results do not impact whether a subsequent test is initiated or canceled.

When ordering STAT panels (such as BRCAplus), the results of the STAT panel will be prioritized and reported with a shorter turnaround time, even if the tests were run concurrently.

Known Familial Variants

Variant-specific report comments about the presence or absence of known familial variant(s) require the "Known Familial Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- Name and date of birth

Variant requests without an internal Ambry reference ID or positive family member's lab report will not receive a variant-specific report comment.

Previously Reported Variants

ExomeNext® or GenomeNext™ report comments about the presence or absence of a variant previously reported **in the patient** require the "Previously Reported Variant" section of this form to be completed accurately, including an internal Ambry reference ID and/or a copy of the positive family member's lab report. Acceptable types of Ambry identifiers include:

- Accession number
- Order number
- Name and date of birth

Previously reported variant requests without an internal Ambry reference ID or positive lab report will not receive a variant-specific report comment.

Variant-specific report comments about the presence or absence of a variant previously reported **in a family member** are not included in ExomeNext, GenomeNext, or Neurology panel reports.